EGFR and non-small cell lung carcinoma: The results indicated that BA at a concentration well below the IC50 (higher than 20 μM for both A549 and H1299 cells) could still synergistically potentiate the antitumor activity of gefitinib or osimertinib against wt-EGFR NSCLC cells.